Evidence map›Paper›PMID 40384398›Full record

ArticleJournal of the International AIDS Society2025

Dosing forgiveness of oral PrEP for cisgender women remains uncertain.

Mia Moore, David Glidden, Peter Anderson, Craig Hendrix, Dobromir Dimitrov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mia MooreVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-5055-7075
David GliddenSchool of Medicine, University of California, San Francisco, California, USA.
Peter AndersonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-1200-8494
Craig HendrixDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-5696-8665
Dobromir DimitrovVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-2842-5436

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
A platform for monitoring the efficacy and optimal dosing of long-acting ARTR01AI170298 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2022 to 2025
$2.6M
Drug concentration measurement for HIV prevention targets: toward a population-based HIV impact assessment (PHIA) for PrEPR01AI179417 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Anna Bershteyn, Dobromir Dimitrov · 2024 to 2026
$2.5M
Statistical methods for clinical trials of novel PrEP agentsR01AI143357 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLIDDEN, DAVID V. · 2018 to 2021
$483k
National Institute of Allergy and Infectious Diseases 1R01AI179417-01A1National Institute of Allergy and Infectious Diseases 5UM1AI068617-20National Institute of Allergy and Infectious Diseases R01AI170298NIAID NIH HHS R01 AI143357NIAID NIH HHS R01 AI170298NIAID NIH HHS R01 AI179417NIAID NIH HHS UM1 AI068617NIDA NIH HHS 5UM1AI068617-20
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40384398
PMCPMC12086362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.